{"database": "press", "table": "releases", "rows": [["https://www.klobuchar.senate.gov/public/index.cfm/news-releases?ID=B155A942-7AB4-40BE-B2D0-95B0129886EF", "Klobuchar Statement on Weight Loss Drug Pricing Announcement", "2025-11-06", "2025", "2025-11", "Democrat", "Senate", "MN", "Amy Klobuchar", "K000367", "www.klobuchar.senate.gov", "klobuchar", "https://www.klobuchar.senate.gov/public/index.cfm/news-releases", "scraper", "WASHINGTON - Today, U.S. Senators Amy Klobuchar (D-MN) released the following statement in response to Eli Lilly and Novo Nordisk\u2019s newly negotiated prices for weight loss drugs for Medicare beneficiaries.\n\n\u201cToday\u2019s announcement of lower prices for Ozempic and other GLP-1 drugs is a direct result of the Medicare drug price negotiations bill that I led and was passed into law in 2022,\u201d said Klobuchar. \"For too long, big drug companies have put profits ahead of the health and well-being of the American people. It\u2019s welcome news that some of the most widely-used medications will now be more affordable thanks to Medicare\u2019s drug price negotiations.\u201d\n\nKlobuchar has long led efforts to lower drug prices. The Empowering Medicare Seniors to Negotiate Drug Prices Act, Klobuchar\u2019s bill to end the ban on Medicare negotiating lower prescription drug prices for Medicare\u2019s 51 million seniors and help lower drug prices for all Americans was signed into law in August 2022.\n\nIn May, Klobuchar, Senator Peter Welch (D-VT), and 25 of their colleagues re-introduced the Strengthening Medicare and Reducing Taxpayer (SMART) Prices Act, which would expand the number of prescription drugs that HHS could negotiate lower prices for and increase the amount of savings Medicare could negotiate.\n\nIn April, two of Klobuchar and Senator Chuck Grassley\u2019s (R-IA) bipartisan bills to promote competition and reduce drug prices - The Preserving Access to Affordable Generics and Biosimilars Act and the Stop STALLING Act - passed the Senate Judiciary Committee by voice vote. Together these bills would save taxpayers $1.9 billion over 10 years.\n\nThe Preserving Access to Affordable Generics and Biosimilars Act would limit anticompetitive \u201cpay-for-delay\u201d deals that prevent or delay the introduction of affordable follow-on versions of branded pharmaceuticals.\n\nThe Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act would deter pharmaceutical companies from filing sham petitions with the Food and Drug Administration (FDA) in order to interfere with the approval of generic and biosimilar medicines that compete with their own brand products, a tactic that delays patient access to affordable medications.\n\n###", 1, "2026-03-30T01:40:41Z", "2026-04-06T19:52:45Z"]], "columns": ["url", "title", "date", "year", "month", "party", "chamber", "state", "member_name", "bioguide_id", "domain", "scraper", "source", "date_source", "text", "has_text", "collected_at", "updated_at"], "primary_keys": ["url"], "primary_key_values": ["https://www.klobuchar.senate.gov/public/index.cfm/news-releases?ID=B155A942-7AB4-40BE-B2D0-95B0129886EF"], "units": {}, "query_ms": 1.4593310188502073, "source": "dwillis/congress-press", "source_url": "https://github.com/dwillis/congress-press", "license": "MIT", "license_url": "https://github.com/dwillis/congress-press/blob/main/LICENSE"}